ArticleScientific reports2026
Effect of intraoral and extraoral photobiomodulation on salivary oxidative stress and inflammatory cytokines in patients with radiotherapy-induced oral mucositis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photobiomodulation (PBM) is an evidence-based approach for managing oral mucositis (OM) in patients undergoing head and neck radiotherapy (RT), though its biological mechanisms remain under investigation. This study evaluated salivary oxidative stress (OS) and inflammatory biomarkers in patients with head and neck squamous cell carcinoma (HNSCC) who received intraoral (IOPBM, n = 10) or extraoral PBM (EOPBM, n = 8) as supportive therapy during radiotherapy, and not as a cancer treatment. Preventive IOPBM/EOPBM were applied five times weekly from RT initiation until OM healing. Twenty healthy individuals served as the control group. Unstimulated saliva was collected at pre-, mid-, and final-RT (last RT session) to assess myeloperoxidase (MPO), malondialdehyde (MDA), superoxide dismutase (SOD), glutathione (GSH), interleukin-6 (IL-6), and interleukin-10 (IL-10). HNSCC patients exhibited altered oxidative and inflammatory biomarker profiles during RT. MDA levels showed a transient increase at mid-RT (p < 0.05), particularly in the IOPBM group, but were not associated with OM severity (p > 0.05). MPO activity was significantly higher at all RT time points and across OM severity grades compared with CT (p < 0.05–0.01). In contrast, SOD activity were consistently elevated throughout RT in PBM-treated patients compared with CT (p < 0.001), and GSH levels increased at mid-RT (p < 0.01). IL-6 and IL-10 levels decreased from pre- to final-RT compared to CT (p < 0.05). Clinically, all patients developed OM, although fewer than 40% experienced severe OM. These findings suggest that PBM enhances antioxidant defenses and modulates inflammatory responses, supporting its role in reducing RT-induced oral toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.